{"id":"fludarabine-cytarabine","safety":{"commonSideEffects":[{"rate":"34%","effect":"Neutropenia"},{"rate":"21%","effect":"Thrombocytopenia"},{"rate":"17%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Fludarabine works by inhibiting the enzyme ribonucleotide reductase, which is necessary for DNA synthesis. This leads to the inhibition of DNA synthesis and cell death in rapidly dividing cells, such as cancer cells.","oneSentence":"Fludarabine is a nucleoside analog that inhibits DNA synthesis by interfering with ribonucleotide reductase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:54:59.437Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia"},{"name":"Non-Hodgkin's lymphoma"}]},"trialDetails":[{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT05780879","phase":"PHASE2","title":"A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2024-06-03","conditions":"Secondary Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT03591510","phase":"PHASE2","title":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-03-13","conditions":"FLT3-mutated Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT03214562","phase":"PHASE1, PHASE2","title":"Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-26","conditions":"High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT07441967","phase":"PHASE2","title":"The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-20","conditions":"Hematologic Malignancies","enrollment":44},{"nctId":"NCT06247787","phase":"PHASE1","title":"A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-02-04","conditions":"Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia","enrollment":36},{"nctId":"NCT07428486","phase":"PHASE1","title":"A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-17","conditions":"Phase I, FLAG Chemotherapy, Lisaftoclax","enrollment":24},{"nctId":"NCT06034470","phase":"PHASE1","title":"Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-12-18","conditions":"Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome","enrollment":30},{"nctId":"NCT06325748","phase":"PHASE1","title":"SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Senti Biosciences","startDate":"2024-04-22","conditions":"AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies","enrollment":21},{"nctId":"NCT05987696","phase":"PHASE1","title":"Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-07-31","conditions":"AML, Adult, Minimal Residual Disease","enrollment":2},{"nctId":"NCT03182244","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2017-10-25","conditions":"AML With FLT3 Mutation","enrollment":276},{"nctId":"NCT07046078","phase":"PHASE2","title":"Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-26","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":20},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT04898894","phase":"PHASE1","title":"Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-11-15","conditions":"Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage","enrollment":37},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT07228273","phase":"PHASE2","title":"Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-12-12","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":102},{"nctId":"NCT05183035","phase":"PHASE3","title":"Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"PedAL BCU, LLC","startDate":"2022-10-01","conditions":"Acute Myeloid Leukemia","enrollment":98},{"nctId":"NCT05317403","phase":"PHASE1","title":"Venetoclax to Augment Epigenetic Modification and Chemotherapy","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-03-31","conditions":"Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory","enrollment":40},{"nctId":"NCT04220684","phase":"PHASE1","title":"Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML","status":"COMPLETED","sponsor":"Sumithira Vasu","startDate":"2020-06-11","conditions":"Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia","enrollment":19},{"nctId":"NCT04240002","phase":"PHASE1, PHASE2","title":"A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2020-09-04","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)","enrollment":9},{"nctId":"NCT07297173","phase":"PHASE1","title":"Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-12-01","conditions":"Relapsed Leukemia, Refractory Leukemia","enrollment":5},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","enrollment":78},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT07153068","phase":"PHASE1, PHASE2","title":"SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-28","conditions":"T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)","enrollment":12},{"nctId":"NCT05955261","phase":"PHASE2","title":"A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-07-25","conditions":"Acute Myeloid Leukemia","enrollment":70},{"nctId":"NCT02421939","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-10-20","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":371},{"nctId":"NCT06001788","phase":"PHASE1","title":"Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2024-02-22","conditions":"AML, AML With Mutated NPM1, Hematologic Malignancy","enrollment":171},{"nctId":"NCT03391466","phase":"PHASE3","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2018-01-25","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":359},{"nctId":"NCT05146739","phase":"PHASE1","title":"Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-10-10","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome","enrollment":8},{"nctId":"NCT07026942","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML","status":"NOT_YET_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2026-04-01","conditions":"Relapsed/Refractory AML","enrollment":42},{"nctId":"NCT06928662","phase":"PHASE1, PHASE2","title":"Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-23","conditions":"Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia","enrollment":36},{"nctId":"NCT07059975","phase":"EARLY_PHASE1","title":"UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML","status":"RECRUITING","sponsor":"Joanna Yi","startDate":"2025-10-22","conditions":"Acute Myeloid Leukemia, Pediatric AML","enrollment":36},{"nctId":"NCT06376162","phase":"PHASE1","title":"Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia","status":"RECRUITING","sponsor":"PedAL BCU, LLC","startDate":"2025-03-18","conditions":"Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia","enrollment":20},{"nctId":"NCT03263936","phase":"PHASE1","title":"Epigenetic Reprogramming in Relapse/Refractory AML","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2017-07-11","conditions":"Acute Myelogenous Leukemia","enrollment":37},{"nctId":"NCT03068819","phase":"PHASE1, PHASE2","title":"Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-10-23","conditions":"Acute Myeloid Leukemia","enrollment":62},{"nctId":"NCT00801489","phase":"PHASE2","title":"Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-04","conditions":"Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","enrollment":270},{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT05712278","phase":"PHASE1","title":"A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2023-06-16","conditions":"Acute Myeloid Leukaemia","enrollment":7},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT07109518","phase":"PHASE1","title":"uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-28","conditions":"Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT06387069","phase":"PHASE3","title":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2024-04-26","conditions":"Acute Myeloid Leukemia","enrollment":316},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT03793478","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-15","conditions":"Acute Myeloid Leukemia","enrollment":65},{"nctId":"NCT07106749","phase":"PHASE1","title":"CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-28","conditions":"Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":"Acute Myeloid Leukemia in Children","enrollment":60},{"nctId":"NCT06220097","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-02-01","conditions":"B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory","enrollment":28},{"nctId":"NCT05521087","phase":"PHASE1","title":"A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2025-12-26","conditions":"Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT06228781","phase":"NA","title":"Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-12-01","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT01350232","phase":"NA","title":"Treatment of Sickle Cell Anemia With Stem Cell Transplant","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2009-09","conditions":"Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia","enrollment":2},{"nctId":"NCT03560908","phase":"PHASE1","title":"Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation","status":"WITHDRAWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2018-07-01","conditions":"Relapsed AML, T(8;21), C-KIT Mutation","enrollment":""},{"nctId":"NCT03813147","phase":"PHASE1","title":"Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-17","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":12},{"nctId":"NCT05586074","phase":"PHASE3","title":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","status":"RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2023-03-03","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":324},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":5000},{"nctId":"NCT01085617","phase":"","title":"Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2010-12","conditions":"Leukemia, Mucositis, Oral Complications","enrollment":""},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT06667973","phase":"PHASE2","title":"Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2025-06","conditions":"Acute Myeloid Leukemia, FLT3 Gene Mutation, Adult AML","enrollment":80},{"nctId":"NCT05870995","phase":"PHASE2","title":"Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-02-01","conditions":"Refractory Leukemia","enrollment":100},{"nctId":"NCT04250051","phase":"PHASE1","title":"Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2020-12-21","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm","enrollment":2},{"nctId":"NCT04623944","phase":"PHASE1","title":"NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nkarta, Inc.","startDate":"2020-09-21","conditions":"Relapsed/Refractory AML, AML, Adult, MDS","enrollment":61},{"nctId":"NCT04029688","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-01-27","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma","enrollment":38},{"nctId":"NCT06741813","phase":"NA","title":"Allo-HSCT vs ASCT in Adult T-LBL","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-01-01","conditions":"T Lymphoblastic Lymphoma","enrollment":230},{"nctId":"NCT02085408","phase":"PHASE3","title":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-02-04","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","enrollment":727},{"nctId":"NCT04526795","phase":"PHASE1","title":"Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-04-09","conditions":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia","enrollment":19},{"nctId":"NCT05476770","phase":"PHASE1","title":"Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies","status":"RECRUITING","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2022-11-11","conditions":"Hematologic Malignancy, AML, ALL","enrollment":54},{"nctId":"NCT05849662","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2024-10-11","conditions":"Leukemia, Juvenile Myelomonocytic, JMML, JCML","enrollment":58},{"nctId":"NCT05601466","phase":"PHASE1","title":"Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-03-26","conditions":"AML, Adult","enrollment":3},{"nctId":"NCT05601830","phase":"PHASE1","title":"Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease","status":"TERMINATED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-10-09","conditions":"Minimal Residual Disease","enrollment":1},{"nctId":"NCT05503134","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-02-14","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT02926586","phase":"PHASE4","title":"Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2017-01-01","conditions":"Acute Myeloid Leukemia, Core-Binding Factor","enrollment":68},{"nctId":"NCT04982354","phase":"PHASE1, PHASE2","title":"Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"Guenther Koehne","startDate":"2022-07-05","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT06571825","phase":"PHASE4","title":"RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR","status":"RECRUITING","sponsor":"He Huang","startDate":"2024-07-17","conditions":"Acute Myeloid Leukemia","enrollment":118},{"nctId":"NCT05326516","phase":"PHASE1","title":"A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2022-03-09","conditions":"Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia","enrollment":30},{"nctId":"NCT06468267","phase":"PHASE2","title":"RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.","status":"RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2024-07-15","conditions":"Peripheral T Cell Lymphoma","enrollment":50},{"nctId":"NCT03616470","phase":"PHASE3","title":"Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"GlycoMimetics Incorporated","startDate":"2018-10-15","conditions":"Acute Myeloid Leukemia","enrollment":388},{"nctId":"NCT03902665","phase":"PHASE2","title":"Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2019-03-15","conditions":"Acute Myeloid Leukemia, Adult","enrollment":19},{"nctId":"NCT06111612","phase":"","title":"Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-01-20","conditions":"Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia","enrollment":50},{"nctId":"NCT02400281","phase":"PHASE1, PHASE2","title":"Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2015-09","conditions":"Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT05807932","phase":"PHASE1, PHASE2","title":"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","status":"RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2023-06-26","conditions":"Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":38},{"nctId":"NCT06336395","phase":"PHASE2","title":"Ma-Spore ALL 2020 Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2020-03-04","conditions":"B Lymphoblastic Leukemia","enrollment":500},{"nctId":"NCT03412409","phase":"PHASE2","title":"RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2018-02-01","conditions":"Acute Leukemia, Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT02013167","phase":"PHASE3","title":"Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-01-03","conditions":"Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","enrollment":405},{"nctId":"NCT02441803","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Leukemia","enrollment":11},{"nctId":"NCT01497002","phase":"PHASE3","title":"Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a","status":"COMPLETED","sponsor":"University of Leipzig","startDate":"2005-04","conditions":"Acute Myeloid Leukaemia","enrollment":1222},{"nctId":"NCT02626338","phase":"PHASE1, PHASE2","title":"Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML","status":"COMPLETED","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2016-02","conditions":"Relapsed/Refractory Acute Myeloid Leukemia (AML)","enrollment":16},{"nctId":"NCT06175702","phase":"","title":"Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2023-12-25","conditions":"Lymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALL","enrollment":150},{"nctId":"NCT05583175","phase":"PHASE2","title":"Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies","status":"UNKNOWN","sponsor":"Xianmin Song, MD","startDate":"2022-11-01","conditions":"Leukemia, Myeloid, Acute, MDS, Hematopoietic Stem Cell Transplantation","enrollment":50},{"nctId":"NCT03961919","phase":"PHASE2","title":"Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant","status":"COMPLETED","sponsor":"Ciceri Fabio","startDate":"2009-02-10","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Transplant-Related Hematologic Malignancy","enrollment":15},{"nctId":"NCT06084819","phase":"PHASE2","title":"Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2023-08-01","conditions":"Relapsed/Refractory Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT02649764","phase":"PHASE1","title":"Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-04","conditions":"Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome","enrollment":15},{"nctId":"NCT02642965","phase":"PHASE1, PHASE2","title":"Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2016-05-02","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia","enrollment":38},{"nctId":"NCT05320380","phase":"PHASE1, PHASE2","title":"A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat","status":"WITHDRAWN","sponsor":"Children's Oncology Group","startDate":"2023-08-01","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia","enrollment":""},{"nctId":"NCT03882203","phase":"PHASE2","title":"CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-08-01","conditions":"Refractory Hematologic Cancer, Allogeneic Stem Cell Transplantation","enrollment":18},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":"Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute","enrollment":153},{"nctId":"NCT02280525","phase":"PHASE1","title":"Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-03-05","conditions":"Leukemia","enrollment":8}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"}],"_approvalHistory":[],"publicationCount":179,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Fludarabine , cytarabine","genericName":"Fludarabine , cytarabine","companyName":"Cooperative Study Group A for Hematology","companyId":"cooperative-study-group-a-for-hematology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fludarabine is a nucleoside analog that inhibits DNA synthesis by interfering with ribonucleotide reductase. Used for Chronic lymphocytic leukemia, Non-Hodgkin's lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}